GlassScriptPhysician profile
Jimmie Mar
NPI 1649705567
$579.98
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $83.35 · 2021: $275 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $103.68 | 2021 | |
| Abbvie INC. | $95.76 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $85.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.97 | 2019-2020 | |
| Pfizer INC. | $74.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.19 | 2022 | |
| Si-Bone, INC. | $30.43 | 2020 | |
| Vapotherm INC | $22.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.97 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmie Mar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.